Cancer Drug Maker BeiGene Takes Action to Mitigate Delisting Risk
Company has changed auditors in a bid to comply with U.S. law and avoid a potential forced delisting from the Nasdaq Key Takeaways: BeiGene has switched auditors for its New…
E&Y Hua Ming
